Advertisement

Low risk of ICH after reperfusion therapy in acute stroke patients treated with direct oral anti-coagulant

      Highlights

      • Frequency of ICH after reperfusion therapy in patients treated with DOAC is low.
      • Factors related to ICH were blood pressure, glucose level and DOAC intake time.
      • The rate of ICH was higher in patients ≤4 h from last DOAC intake than those >4 h.

      Abstract

      Background

      The safety of intravenous thrombolysis (IVT) and endovascular therapy (EVT) in patients treated with DOAC is unclear. We investigated whether recanalization therapy in patients treated with DOAC is safe.

      Methods

      A nationwide, multicenter, retrospective cohort questionnaire survey was conducted to investigate the: (1) frequency of intracerebral hemorrhage (ICH) after recanalization therapy in patients treated with DOAC; (2) independent factors related to ICH; (3) relationship between last intake time of DOAC and ICH; and (4) comparison of ICH frequency between patients treated with DOAC, vitamin K antagonist (VKA), and no-anticoagulation (no-ACT) (control).

      Results

      One hundred eighteen stroke centers returned the questionnaire and 100 patients (56 IVT alone, 29 EVT alone, and 15 both IVT and EVT) on DOAC were registered. The frequency of asymptomatic and symptomatic (≥4-point NIHSS score increase) ICH within 24 h in DOAC patients were 18% and 2%, and were not different compared with the VKA and no-ACT groups (p = 0.728; and p = 0.626). On multivariate analysis, systolic blood pressure (OR, 1.04; p < 0.001) and blood glucose (OR, 1.02; p = 0.019) were independent factors for ICH. Among the 52 patients with a known last intake time of DOAC, the rate of ICH was higher in patients ≤4 h from last intake than those >4 h (38% vs. 10%, p = 0.033).

      Conclusions

      Risk of ICH after reperfusion therapy in patients treated with DOAC should be low. Systolic blood pressure, glucose level, and DOAC intake time appear to be factors for ICH.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Singer D.E.
        • Chang Y.
        • Fang M.C.
        • Borowsky L.H.
        • Pomernacki N.K.
        • Udaltsova N.
        • et al.
        The net clinical benefit of warfarin anticoagulation in atrial fibrillation.
        Ann. Intern. Med. 2009; 151: 297-305
        • Camm A.J.
        • Lip G.Y.
        • De Caterina R.
        • Savelieva I.
        • Atar D.
        Hohnloser SH, et al. 2012 focused update of the esc guidelines for the management of atrial fibrillation: an update of the 2010 esc guidelines for the management of atrial fibrillation. Developed with the special contribution of the european heart rhythm association.
        Eur. Heart J. 2012; 33: 2719-2747
        • January C.T.
        • Wann L.S.
        • Alpert J.S.
        • Calkins H.
        • Cigarroa J.E.
        • Cleveland J.C.
        • et al.
        2014 aha/acc/hrs guideline for the management of patients with atrial fibrillation: executive summary: a report of the american college of cardiology/american heart association task force on practice guidelines and the heart rhythm society.
        Circulation. 2014; 130: 2071-2104
        • Ruff C.T.
        • Giugliano R.P.
        • Braunwald E.
        • Hoffman E.B.
        • Deenadayalu N.
        • Ezekowitz M.D.
        • et al.
        Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
        Lancet. 2014; 383: 955-962
        • Tissue plasminogen activator for acute ischemic stroke
        The national institute of neurological disorders and stroke rt-pa stroke study group.
        N. Engl. J. Med. 1995; 333: 1581-1587
        • Berkhemer O.A.
        • Fransen P.S.
        • Beumer D.
        • van den Berg L.A.
        • Lingsma H.F.
        • Yoo A.J.
        • et al.
        A randomized trial of intraarterial treatment for acute ischemic stroke.
        N. Engl. J. Med. 2015; 372: 11-20
        • Goyal M.
        • Demchuk A.M.
        • Menon B.K.
        • Eesa M.
        • Rempel J.L.
        • Thornton J.
        • et al.
        Randomized assessment of rapid endovascular treatment of ischemic stroke.
        N. Engl. J. Med. 2015; 372: 1019-1030
        • Campbell B.C.
        • Mitchell P.J.
        • Kleinig T.J.
        • Dewey H.M.
        • Churilov L.
        • Yassi N.
        • et al.
        Endovascular therapy for ischemic stroke with perfusion-imaging selection.
        N. Engl. J. Med. 2015; 372: 1009-1018
        • Saver J.L.
        • Goyal M.
        • Bonafe A.
        • Diener H.C.
        • Levy E.I.
        • Pereira V.M.
        • et al.
        Stent-retriever thrombectomy after intravenous t-pa vs. T-pa alone in stroke.
        N. Engl. J. Med. 2015; 372: 2285-2295
        • Molina C.A.
        • Chamorro A.
        • Rovira A.
        • de Miquel A.
        • Serena J.
        • Roman L.S.
        • et al.
        Revascat: a randomized trial of revascularization with solitaire fr device vs. best medical therapy in the treatment of acute stroke due to anterior circulation large vessel occlusion presenting within eight-hours of symptom onset.
        Int. J. Stroke. 2015; 10: 619-626
        • Jauch E.C.
        • Saver J.L.
        • Adams Jr., H.P.
        • Bruno A.
        • Connors J.J.
        • Demaerschalk B.M.
        • et al.
        Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2013; 44: 870-947
        • Powers W.J.
        • Derdeyn C.P.
        • Biller J.
        • Coffey C.S.
        • Hoh B.L.
        • Jauch E.C.
        • et al.
        2015 american heart association/american stroke association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the american heart association/american stroke association.
        Stroke. 2015; 46: 3020-3035
        • Minematsu K.
        • Toyoda K.
        • Hirano T.
        • Kimura K.
        • Kondo R.
        • Mori E.
        • et al.
        Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, october 2012: a guideline from the japan stroke society.
        J. Stroke Cerebrovasc. Dis. 2013; 22: 571-600
        • Seiffge D.J.
        • Hooff R.J.
        • Nolte C.H.
        • Bejot Y.
        • Turc G.
        • Ikenberg B.
        • et al.
        Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome.
        Circulation. 2015; 132: 1261-1269
        • Saji N.
        • Kimura K.
        • Aoki J.
        • Uemura J.
        • Sakamoto Y.
        Intracranial hemorrhage caused by non-vitamin k antagonist oral anticoagulants (NOACS)- multicenter retrospective cohort study in japan.
        Circ. J. 2015; 79: 1018-1023
        • Larrue V.
        • von Kummer R.R.
        • Müller A.
        • Bluhmki E.
        Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).
        Stroke. 2001; 32: 438-441
        • Xian Y.
        • Liang L.
        • Smith E.E.
        • Schwamm L.H.
        • Reeves M.J.
        • Olson D.M.
        • et al.
        Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.
        JAMA. 2012; 307: 2600-2608
        • De Marchis G.M.
        • Jung S.
        • Colucci G.
        • Meier N.
        • Fischer U.
        • Weck A.
        • et al.
        Intracranial hemorrhage, outcome, and mortality after intra-arterial therapy for acute ischemic stroke in patients under oral anticoagulants.
        Stroke. 2011; 42: 3061-3066
        • Nogueira R.G.
        • Smith W.S.
        Safety and efficacy of endovascular thrombectomy in patients with abnormal hemostasis: pooled analysis of the merci and multi merci trials.
        Stroke. 2009; 40: 516-522
        • Matute M.C.
        • Guillan M.
        • Garcia-Caldentey J.
        • Buisan J.
        • Aparicio M.
        • Masjuan J.
        • et al.
        Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran.
        Thromb. Haemost. 2011; 106: 178-179
        • Chatterjee S.
        • Sardar P.
        • Biondi-Zoccai G.
        • Kumbhani D.J.
        New oral anticoagulants and the risk of intracranial hemorrhage: traditional and bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation.
        JAMA Neurol. 2013; 70: 1486-1490
        • Ploen R.
        • Sun L.
        • Zhou W.
        • Heitmeier S.
        • Zorn M.
        • Jenetzky E.
        • et al.
        Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke.
        J. Cereb. Blood Flow Metab. 2014; 34: 495-501
        • Kono S.
        • Yamashita T.
        • Deguchi K.
        • Omote Y.
        • Yunoki T.
        • Sato K.
        • et al.
        Rivaroxaban and apixaban reduce hemorrhagic transformation after thrombolysis by protection of neurovascular unit in rat.
        Stroke. 2014; 45: 2404-2410
        • Shahjouei S.
        • Tsivgoulis G.
        • Bavarsad Shahripour R.
        • Jones G.M.
        • Alexandrov A.V.
        • Zand R.
        Safety of intravenous thrombolysis among stroke patients taking new oral anticoagulants-case series and systematic review of reported cases.
        J. Stroke Cerebrovasc. Dis. 2015; 24: 2685-2693
        • Mazya M.
        • Egido J.A.
        • Ford G.A.
        • Lees K.R.
        • Mikulik R.
        • Toni D.
        • et al.
        Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe implementation of treatments in stroke (sits) symptomatic intracerebral hemorrhage risk score.
        Stroke. 2012; 43: 1524-1531
        • Strbian D.
        • Engelter S.
        • Michel P.
        • Meretoja A.
        • Sekoranja L.
        • Ahlhelm F.J.
        • et al.
        Symptomatic intracranial hemorrhage after stroke thrombolysis: the sedan score.
        Ann. Neurol. 2012; 71: 634-641
        • Menon B.K.
        • Saver J.L.
        • Prabhakaran S.
        • Reeves M.
        • Liang L.
        • Olson D.M.
        • et al.
        Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator.
        Stroke. 2012; 43: 2293-2299
        • Endo K.
        • Kario K.
        • Koga M.
        • Nakagawara J.
        • Shiokawa Y.
        • Yamagami H.
        • et al.
        Impact of early blood pressure variability on stroke outcomes after thrombolysis: the samurai rt-pa registry.
        Stroke. 2013; 44: 816-818
        • Paciaroni M.
        • Agnelli G.
        • Corea F.
        • Ageno W.
        • Alberti A.
        • Lanari A.
        • et al.
        Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study.
        Stroke. 2008; 39: 2249-2256
        • Pulsinelli W.A.
        • Waldman S.
        • Rawlinson D.
        • Plum F.
        Moderate hyperglycemia augments ischemic brain damage: a neuropathologic study in the rat.
        Neurology. 1982; 32: 1239-1246
        • Dietrich W.D.
        • Alonso O.
        • Busto R.
        Moderate hyperglycemia worsens acute blood-brain barrier injury after forebrain ischemia in rats.
        Stroke. 1993; 24: 111-116
        • Ribo M.
        • Molina C.
        • Montaner J.
        • Rubiera M.
        • Delgado-Mederos R.
        • Arenillas J.F.
        • et al.
        Acute hyperglycemia state is associated with lower tpa-induced recanalization rates in stroke patients.
        Stroke. 2005; 36: 1705-1709
        • Ogawa S.
        • Koretsune Y.
        • Yasaka M.
        • Aizawa Y.
        • Atarashi H.
        • Inoue H.
        • et al.
        Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents.
        Circ. J. 2011; 75: 1539-1547
        • Stangier J.
        • Rathgen K.
        • Stahle H.
        • Gansser D.
        • Roth W.
        The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
        Br. J. Clin. Pharmacol. 2007; 64: 292-303
        • Hillarp A.
        • Baghaei F.
        • Fagerberg Blixter I.
        • Gustafsson K.M.
        • Stigendal L.
        • Sten-Linder M.
        • et al.
        Effects of the oral, direct factor xa inhibitor rivaroxaban on commonly used coagulation assays.
        J. Thromb. Haemost. 2011; 9: 133-139
        • Pollack Jr., C.V.
        • Reilly P.A.
        • Eikelboom J.
        • Glund S.
        • Verhamme P.
        • Bernstein R.A.
        • et al.
        Idarucizumab for dabigatran reversal.
        N. Engl. J. Med. 2015; 373: 511-520
        • Yamaguchi T.
        • Mori E.
        • Minematsu K.
        • Nakagawara J.
        • Hashi K.
        • Saito I.
        • et al.
        Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan alteplase clinical trial (j-act).
        Stroke. 2006; 37: 1810-1815